Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Surgical details of PIPAC/PITAC

From: Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma

Data items Number Percent
Patients with primary non-access for PIPAC 7 / 29 24.1
Patients with secondary non-access for PIPAC 3 / 29 10.3
PIPAC procedures per patient (n)
 - 10 x 1 / 29 3.4
 - 7 x 1 / 29 3.4
 - 5 x 1 / 29 3.4
 - 4 x 4 / 29 13.8
 - 3 x 5 / 29 17.2
 - 2 x 8 / 29 27.6
 - 1 x 5 / 29 17.2
 - 0 x 4 / 29 13.8
Number of successful PIPAC/PITAC procedures 79 100
 - Laparoscopic PIPAC procedures 71 / 79 89.9
 - Laparotomy, adhesiolysis +/− debulking & PIPAC 3 / 79 3.8
 - PITAC procedures 5 / 79 6.3
Overall postoperative morbidity/mortality (CTCAE v 4.0)
 - Grade 1 23 / 79 29.1
 - Grade 2 7 / 79 8.9
 - Grade 3 1 / 79 1.3
 - Grade 4 2 / 79 2.5
 - Grade 5 1 / 79 1.3
Media survival time (days) according to tumor regression grade
 - Grade 0 6 226 (31–708)
 - Grade 1 11 360 (135–529)
 - Grade 2+ 8 360 (175–1331)
  1. PIPAC Pressurized IntraPeritoneal Aerosol Chemotherapy, PITAC Pressurized IntraThoracal Aerosol Chemotherapy